Holen Sie sich die Stockscreener-App
0.6604
5.66%
-0.0396
Handel nachbörslich:
.65
-0.0104
-1.57%
Schlusskurs vom Vortag:
$0.70
Offen:
$0.6861
24-Stunden-Volumen:
253.78K
Relative Volume:
0.40
Marktkapitalisierung:
$36.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.56M
KGV:
-0.5644
EPS:
-1.17
Netto-Cashflow:
$-35.28M
1W Leistung:
-5.56%
1M Leistung:
-4.32%
6M Leistung:
-44.97%
1J Leistung:
-49.59%
1-Tages-Spanne:
$0.6423
$0.6868
1-Wochen-Bereich:
$0.6298
$0.712
52-Wochen-Spanne:
$0.6012
$1.915
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corporation
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.6604 | 38.30M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corporation Aktie (PDSB) Neueste Nachrichten
PDS Biotechnology (PDSB) CEO receives 548,782-share stock option award - Stock Titan
[Form 4] PDS Biotechnology Corp Insider Trading Activity - Stock Titan
PDS Biotechnology (PDSB) awards 150,000 stock options to Chief Scientific Officer - Stock Titan
PDS Biotechnology (PDSB) CMO receives grant of 300,000 stock options - Stock Titan
PDS Biotechnology (PDSB) director Ilian Iliev receives grant of 54,876 stock options - Stock Titan
Director option grant at PDS Biotechnology (PDSB) totals 54,876 options - Stock Titan
PDS Biotechnology (PDSB) director awarded 54,876 stock options in new grant - Stock Titan
PDS Biotechnology receives Nasdaq notice for minimum bid price deficiency - Investing.com
Nasdaq warns PDS Biotechnology (NASDAQ: PDSB) on $1.00 bid price rule - Stock Titan
Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB) - The Wall Street Transcript
PDS Biotech Announces Amended Protocol for Phase 3 Trial - National Today
PDSB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail
PDS Biotech (NASDAQ: PDSB) highlights HPV16 trial gains and pipeline - Stock Titan
Will PDS Biotechnology Corporation stock outperform Dow Jones indexMarket Movers & Consistent Profit Focused Trading Strategies - mfd.ru
PDS Biotechnology Amends Late-Stage Trial for PDS0101 to Support Accelerated Approval Pathway in HPV16-Positive Head and Neck Cancer - marketscreener.com
PDS Biotech amends Phase 3 trial to add accelerated approval path - Investing.com
LiveRamp Holdings, Inc. has announced a partnership with Scowtt - Bitget
Nucor has announced that Jack Sullivan has been promoted to Chief Financial Officer, Treasurer, and Executive Vice President of the company. - Bitget
PDS Biotechnology Corporation (PDS Biotech) recently announced that it has made significant amendments to the study protocol of its Phase III clinical trial, Versatile-003. - Bitget
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - The Manila Times
Cancer trial shift seeks faster PDS0101 bid for HPV16 head and neck patients - Stock Titan
Published on: 2026-02-19 10:39:09 - baoquankhu1.vn
PDS Biotechnology Approaches Critical Regulatory and Clinical Milestones - AD HOC NEWS
Is PDS Biotechnology Corporation likely to announce a buybackQuarterly Trade Review & AI Driven Price Predictions - mfd.ru
Can PDS Biotechnology Corporation stock outperform in a bear marketWeekly Trade Review & Daily Volume Surge Signals - mfd.ru
PDS Biotech’s Big Bet Rides On Two Trial Readouts - Finimize
Growth Review: Can PDS Biotechnology Corporation stock outperform in a bear marketJuly 2025 Update & Weekly High Momentum Picks - baoquankhu1.vn
PDS Biotechnology: Regulatory Agreement Paves Way for Accelerated Cancer Therapy Review - AD HOC NEWS
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study By Investing.com - Investing.com South Africa
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study - Investing.com Nigeria
PDS Biotechnology Corporation Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI - marketscreener.com
PDS Biotechnology Corporation Reports 9.6 Months Median Progression-Free Survival from NCI-Led Study of PDS01ADC in Advanced Prostate Cancer - Quiver Quantitative
PDS Biotech Announces Presentation of Preliminary Results - GlobeNewswire
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI - The Manila Times
PDS Biotech secures patent for cancer immunotherapy PDS0101 By Investing.com - Investing.com Nigeria
PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection - TipRanks
PDS Biotech secures patent for cancer immunotherapy PDS0101 - Investing.com
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - The Manila Times
Aug Macro: Can PDS Biotechnology Corporation stock outperform in a bear market2025 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Miss: Can STRW maintain sales growthMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Growth Value: Is PDS Biotechnology Corporation trading at a discount - baoquankhu1.vn
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
PDS Biotechnology Corporation (PDSB) stock: surges as FDA protocol amendment aims for accelerated approval - parameter.io
PDS Biotech stock soars after FDA meeting provides accelerated approval path By Investing.com - Investing.com South Africa
PDS Biotech stock soars after FDA meeting provides accelerated approval path - Investing.com Nigeria
PDS Biotech Announces FDA Alignment on Use of Progression Free Survival as Primary Endpoint - marketscreener.com
PDS Biotech submits amended protocol for phase 3 cancer trial By Investing.com - Investing.com India
PDS Biotech Files Amended Protocol for Phase 3 VERSATILE-003 Trial to Seek Accelerated Approval of PDS0101 - Quiver Quantitative
Cancer trial tweak could get a new head and neck treatment to patients faster - Stock Titan
How institutional buying supports PDS Biotechnology Corporation stockJuly 2025 Fed Impact & Free Reliable Trade Execution Plans - Улправда
Finanzdaten der Pds Biotechnology Corporation-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):